

Maria Gudbrandsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2616735/publications.pdf>

Version: 2024-02-01

23
papers

628
citations

840585

11
h-index

642610

23
g-index

28
all docs

28
docs citations

28
times ranked

1691
citing authors

#	ARTICLE	IF	CITATIONS
1	Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study. <i>Molecular Psychiatry</i> , 2023, 28, 1995-2006.	4.1	13
2	Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs. <i>Human Brain Mapping</i> , 2022, 43, 300-328.	1.9	30
3	Is postnatal depression a distinct subtype of major depressive disorder? An exploratory study. <i>Archives of Women's Mental Health</i> , 2021, 24, 329-333.	1.2	4
4	Examining volumetric gradients based on the frustum surface ratio in the brain in autism spectrum disorder. <i>Human Brain Mapping</i> , 2021, 42, 953-966.	1.9	4
5	Atypical measures of diffusion at the gray-white matter boundary in autism spectrum disorder in adulthood. <i>Human Brain Mapping</i> , 2021, 42, 467-484.	1.9	11
6	Maternal depression during pregnancy alters infant subcortical and midbrain volumes. <i>Journal of Affective Disorders</i> , 2021, 291, 163-170.	2.0	14
7	Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion. <i>Molecular Psychiatry</i> , 2021, 26, 4496-4510.	4.1	87
8	Large-scale mapping of cortical alterations in 22q11.2 deletion syndrome: Convergence with idiopathic psychosis and effects of deletion size. <i>Molecular Psychiatry</i> , 2020, 25, 1822-1834.	4.1	122
9	Altered white matter microstructure in 22q11.2 deletion syndrome: a multisite diffusion tensor imaging study. <i>Molecular Psychiatry</i> , 2020, 25, 2818-2831.	4.1	50
10	Magnitude and heterogeneity of brain structural abnormalities in 22q11.2 deletion syndrome: a meta-analysis. <i>Molecular Psychiatry</i> , 2020, 25, 1704-1717.	4.1	39
11	Patterns of Cortical Folding Associated with Autistic Symptoms in Carriers and Noncarriers of the 22q11.2 Microdeletion. <i>Cerebral Cortex</i> , 2020, 30, 5281-5292.	1.6	3
12	Neuroanatomical underpinnings of autism symptomatology in carriers and non-carriers of the 22q11.2 microdeletion. <i>Molecular Autism</i> , 2020, 11, 46.	2.6	8
13	Mapping Subcortical Brain Alterations in 22q11.2 Deletion Syndrome: Effects of Deletion Size and Convergence With Idiopathic Neuropsychiatric Illness. <i>American Journal of Psychiatry</i> , 2020, 177, 589-600.	4.0	55
14	Glutamatergic function in a genetic high-risk group for psychosis: A proton magnetic resonance spectroscopy study in individuals with 22q11.2 deletion. <i>European Neuropsychopharmacology</i> , 2019, 29, 1333-1342.	0.3	8
15	Father-infant interactions and infant regional brain volumes: A cross-sectional MRI study. <i>Developmental Cognitive Neuroscience</i> , 2019, 40, 100721.	1.9	18
16	The Neuroanatomy of Autism Spectrum Disorder Symptomatology in 22q11.2 Deletion Syndrome. <i>Cerebral Cortex</i> , 2019, 29, 3655-3665.	1.6	8
17	S181. THE STATE OR TRAIT COMPONENT OF DOPAMINE AND GLUTAMATE DYSFUNCTION IN THE RISK FOR PSYCHOSIS: AN IN VIVO MULTIMODAL IMAGING STUDY OF INDIVIDUALS WITH 22Q11.2 DELETION. <i>Schizophrenia Bulletin</i> , 2018, 44, S395-S395.	2.3	1
18	In Vivo Evidence of Reduced Integrity of the Gray-White Matter Boundary in Autism Spectrum Disorder. <i>Cerebral Cortex</i> , 2017, 27, 877-887.	1.6	41

#	ARTICLE	IF	CITATIONS
19	Motherâ€™infant interactions and regional brain volumes in infancy: an MRI study. <i>Brain Structure and Function</i> , 2017, 222, 2379-2388.	1.2	37
20	Olanzapine and risperidone plasma concentration therapeutic drug monitoring: A feasibility study. <i>Journal of Psychopharmacology</i> , 2015, 29, 933-942.	2.0	3
21	Response inhibition and serotonin in autism: a functional MRI study using acute tryptophan depletion. <i>Brain</i> , 2014, 137, 2600-2610.	3.7	48
22	Psychiatrists' Perspectives on Antipsychotic Dose and the Role of Plasma Concentration Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 486-493.	1.0	19
23	Poster #S244 CONSULTANT PSYCHIATRISTS' PERSPECTIVES REGARDING ANTIPSYCHOTIC DOSE CHOICE AND PLASMA CONCENTRATION THERAPEUTIC DRUG MONITORING. <i>Schizophrenia Research</i> , 2014, 153, S178.	1.1	1